News FDA experts to vote on Spark's groundbreaking gene therapy Luxturna could be single life-changing injection
News Spark files revolutionary gene therapy with FDA Luxturna granted six-month priority review by FDA.
News Submission completed, Spark sets sight on first ever US gene... Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness.
News Spark and Pfizer's haemophilia gene therapy gets European PR... Decision based on promising data from ongoing phase 1/2 trial.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News Spark’s gene therapy shows great promise in restoring sight Philadelphia-based company could be frontrunner in gene therapy
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.